Text Size

An Eighteen Month Efficacy and Safety Study in Obese Patients

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00131430
First received: August 16, 2005
Last updated: October 6, 2009
Last verified: October 2009
History of Changes
  Purpose

A study to determine the safety and efficacy of an investigational drug in patients with obesity.


Condition Intervention Phase
Obesity and Obesity-related Medical Conditions
 Drug: taranabant
 Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: An 18-Month Study to Assess the Safety, Tolerability, and Efficacy of MK0364 in Obese Patients

Resource links provided by NLM:

MedlinePlus related topics: Obesity
U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:
  • After 24 weeks, body weight, safety, and tolerability [ Time Frame: After 24 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • After 80 weeks, body weight [ Time Frame: After 80 weeks ] [ Designated as safety issue: No ]

Enrollment: 500
Study Start Date: September 2005
Study Completion Date: November 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: taranabant
    Other Name: MK0364
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Obese patients with a body mass index between 30kg/m2 and 43 kg/m2, inclusive (BMI between 27 kg/m2 and 43kg/m2, inclusive for those with obesity-related comorbidities including hypertension, dyslipidemia and sleep apnea).

Exclusion Criteria:

  • Patients with serious or unstable current or past medical conditions.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00131430

Sponsors and Collaborators
Merck
Investigators
Study Director: Medical Monitor Merck
  More Information

No publications provided

Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
ClinicalTrials.gov Identifier: NCT00131430     History of Changes
Other Study ID Numbers: 2005_044, MK0364-020
Study First Received: August 16, 2005
Last Updated: October 6, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
 Overweight
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on May 22, 2013